ACADIA PHARMACEUTICALS INC
ACADNasdaq
$25.60
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +13.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.4B
Enterprise Value
$3.6B
P/E
11.6
P/S
4.0
P/B
3.5
EV/EBITDA
43.6
PEG
—
FCF Yield
2.6%
Dividend Yield
—
Revenue (TTM)
$1.1B
Net Income (TTM)
$375.6M
Free Cash Flow (TTM)
$113.6M
Gross Margin
—
Operating Margin
7.4%
Net Margin
34.3%
ROE
30.1%
ROIC
20.4%
Debt / Equity
—
Net Cash
$851.5M
Return 1Y
+13.5%
Company profile
ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
- CEO
- Stephen R. Davis
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 510
- Headquarters
- California
- Website
- acadia-pharm.com
Management & directors
- Kihara JamesPRINCIPAL ACCOUNTING OFFICER
- Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
- Owen Catherine E.Chief Executive Officer
- Rhodes Jennifer JEVP, CHIEF LEGAL OFFICER, SEC
- Thompson Elizabeth H.Z.EVP, Head of Research & Dev
Roles derived from SEC Form 4 filings.
Earnings
ACAD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$268.1M↑ +9.7%
Diluted EPS$0.02↓ -81.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.1B |
| Gross profit | $431.5M | $473.3M | $507.1M | $684.8M | — | — |
| Operating income | -$286.6M | -$170.4M | -$223.6M | -$73.4M | $230.8M | $104.8M |
| Net income | -$281.6M | -$168.0M | -$214.0M | -$61.0M | $226.0M | $391.0M |
| Diluted EPS | -$1.79 | -$1.05 | -$1.34 | -$0.37 | $1.36 | $2.30 |
| Operating cash flow | -$136.2M | -$125.7M | -$114.0M | $16.7M | $157.7M | $109.8M |
| Free cash flow | -$143.8M | -$126.8M | -$114.0M | $16.7M | $157.2M | $105.1M |
| Gross margin | 97.7% | 97.8% | 98.0% | 94.3% | — | — |
| Operating margin | -64.9% | -35.2% | -43.2% | -10.1% | 24.1% | 9.8% |
| Net margin | -63.7% | -34.7% | -41.4% | -8.4% | 23.6% | 36.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $242.0M | $250.4M | $259.6M | $244.3M | $264.6M | $278.6M | $284.0M | $268.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $30.4M | $31.6M | $153.5M | $19.3M | $32.4M | $35.8M | $17.4M | -$4.6M |
| Net income | $33.4M | $32.8M | $143.3M | $19.0M | $26.7M | $71.8M | $273.6M | $3.6M |
| Diluted EPS | $0.20 | $0.20 | $0.86 | $0.11 | $0.16 | $0.42 | $1.61 | $0.02 |
| Operating cash flow | $25.0M | $63.2M | $40.4M | $20.3M | $64.0M | $74.3M | -$48.7M | $34.0M |
| Free cash flow | — | $63.2M | — | $20.3M | $63.7M | $73.9M | -$52.7M | $28.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 12.6% | 12.6% | 59.1% | 7.9% | 12.2% | 12.8% | 6.1% | -1.7% |
| Net margin | 13.8% | 13.1% | 55.2% | 7.8% | 10.1% | 25.8% | 96.3% | 1.4% |
Company news
Jul 11, 2026
Jul 10, 2026
- 10d agoIs ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?finance.yahoo.com
- 10d agoHow CHMP’s Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investorsfinance.yahoo.com
- 10d agoVerastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-26 | Kihara James· PRINCIPAL ACCOUNTING OFFICER | Sale | 11,421 | $26.08 | $297,912.22 | filing |
| 2026-05-29 | BAKER BROS. ADVISORS LP | Award | 18,622 | $0.00 | $0.00 | filing |
| 2026-05-29 | BAKER BROS. ADVISORS LP | Award | 18,622 | $0.00 | $0.00 | filing |
| 2026-05-29 | Brege Laura | Option exercise | 8,107 | — | — | filing |
| 2026-05-29 | Poole Jonathan | Option exercise | 2,010 | — | — | filing |
| 2026-05-29 | Daly James M | Option exercise | 8,107 | — | — | filing |
| 2026-05-29 | GAROFALO ELIZABETH A. | Option exercise | 8,107 | — | — | filing |
| 2026-05-29 | HARRIGAN EDMUND | Option exercise | 8,107 | — | — | filing |
| 2026-05-29 | Ndu Adora | Option exercise | 8,107 | — | — | filing |
| 2026-05-26 | Kihara James· PRINCIPAL ACCOUNTING OFFICER | Sale | 5,401 | $21.18 | $114,393.18 | filing |
| 2026-05-04 | Schneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER | Sale | 3,506 | $21.79 | $76,395.74 | filing |
| 2026-05-04 | Kihara James· PRINCIPAL ACCOUNTING OFFICER | Sale | 1,332 | $21.79 | $29,024.28 | filing |
| 2026-05-01 | Kihara James· PRINCIPAL ACCOUNTING OFFICER | Option exercise | 2,596 | — | — | filing |
| 2026-05-01 | Schneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER | Option exercise | 6,815 | — | — | filing |
| 2026-04-07 | Schneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER | Sale | 2,709 | $22.20 | $60,139.80 | filing |
| 2026-04-07 | Kihara James· PRINCIPAL ACCOUNTING OFFICER | Sale | 1,030 | $22.20 | $22,866.00 | filing |
| 2026-04-05 | Schneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER | Option exercise | 5,276 | — | — | filing |
| 2026-04-05 | Kihara James· PRINCIPAL ACCOUNTING OFFICER | Option exercise | 2,010 | — | — | filing |
| 2026-03-26 | Schneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER | Sale | 3,171 | $21.65 | $68,652.15 | filing |
| 2026-03-26 | Kihara James· PRINCIPAL ACCOUNTING OFFICER | Sale | 1,097 | $21.65 | $23,750.05 | filing |
| 2026-03-26 | Schneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER | Sale | 37 | $21.72 | $803.54 | filing |
| 2026-03-26 | Kihara James· PRINCIPAL ACCOUNTING OFFICER | Sale | 12 | $21.73 | $260.70 | filing |
| 2026-03-25 | Owen Catherine E.· Chief Executive Officer | Sale | 11,641 | $21.47 | $249,932.27 | filing |
| 2026-03-25 | Schneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER | Sale | 4,177 | $21.47 | $89,680.19 | filing |
| 2026-03-25 | Rhodes Jennifer J· EVP, CHIEF LEGAL OFFICER, SEC | Sale | 3,844 | $21.47 | $82,530.68 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.